Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.3% year on year to $636.5 million. The company expects the full year’s revenue to be around $2.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.16 per share was significantly above analysts’ consensus estimates.
Is now the time to buy Fortrea? Find out by accessing our full research report, it’s free.
Fortrea (FTRE) Q1 CY2026 Highlights:
- Revenue: $636.5 million vs analyst estimates of $627.5 million (2.3% year-on-year decline, 1.4% beat)
- Adjusted EPS: $0.16 vs analyst estimates of $0.05 (significant beat)
- Adjusted EBITDA: $47 million vs analyst estimates of $34.61 million (7.4% margin, 35.8% beat)
- The company reconfirmed its revenue guidance for the full year of $2.6 billion at the midpoint
- EBITDA guidance for the full year is $205 million at the midpoint, above analyst estimates of $201.8 million
- Operating Margin: -0.5%, up from -79.9% in the same quarter last year
- Free Cash Flow was -$25 million compared to -$127.1 million in the same quarter last year
- Market Capitalization: $1.16 billion
“We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion,” said Anshul Thakral, CEO of Fortrea.
Company Overview
Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ:FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device companies develop and bring their products to market through clinical trials and support services.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Fortrea’s demand was weak over the last four years as its sales fell at a 3.1% annual rate. This was below our standards and suggests it’s a low quality business.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a stretched historical view may miss recent innovations or disruptive industry trends. Fortrea’s annualized revenue declines of 1.8% over the last two years suggest its demand continued shrinking. 
This quarter, Fortrea’s revenue fell by 2.3% year on year to $636.5 million but beat Wall Street’s estimates by 1.4%.
Looking ahead, sell-side analysts expect revenue to decline by 3.3% over the next 12 months, similar to its two-year rate. This projection is underwhelming and suggests its products and services will see some demand headwinds.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.
Fortrea was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 8% was weak for a healthcare business.
Looking at the trend in its profitability, Fortrea’s adjusted operating margin decreased by 5.2 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 2 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
This quarter, Fortrea generated an adjusted operating margin profit margin of 1.3%, down 2.2 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue.
Cash Is King
Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king.
Fortrea has shown mediocre cash profitability relative to peers over the last five years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 3.8%, below what we’d expect for a healthcare business.
Taking a step back, an encouraging sign is that Fortrea’s margin expanded by 5.9 percentage points during that time. The company’s improvement shows it’s heading in the right direction, and we can see it became a less capital-intensive business because its free cash flow profitability rose while its operating profitability fell.
Fortrea burned through $25 million of cash in Q1, equivalent to a negative 3.9% margin. The company’s cash burn slowed from $127.1 million of lost cash in the same quarter last year. These numbers deviate from its longer-term margin, indicating it is a seasonal business that must build up inventory during certain quarters.
Key Takeaways from Fortrea’s Q1 Results
It was good to see Fortrea beat analysts’ EPS expectations this quarter. We were also happy its revenue narrowly outperformed Wall Street’s estimates. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 5.8% to $12.96 immediately following the results.
Fortrea may have had a good quarter, but does that mean you should invest right now? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).